Supernus Pharmaceuticals SUPN Common Stock Par Value Per Share
Common Stock Par Value Per Share at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's common stock par value per share.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's common stock par value per share?
- Supernus Pharmaceuticals (SUPN) reported common stock par value per share of $0.00 in Q1 2026.
- How has Supernus Pharmaceuticals's common stock par value per share changed year-over-year?
- Supernus Pharmaceuticals's common stock par value per share decreased by 0.0% year-over-year, from $0.00 to $0.00.
- What is the long-term trend for Supernus Pharmaceuticals's common stock par value per share?
- Over 5 years (2020 to 2025), Supernus Pharmaceuticals's common stock par value per share has grown at a 0.0% compound annual growth rate (CAGR), from $0.00 to $0.00.
- What does common stock par value per share mean?
- The par value of common stock is the arbitrary legal value assigned to each share of common stock at the time of issuance. It is a legacy accounting requirement that has little impact on the actual market value or trading price of the shares.